Compare STKS & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STKS | SGMT |
|---|---|---|
| Founded | 2004 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.4M | 169.4M |
| IPO Year | 2011 | 2021 |
| Metric | STKS | SGMT |
|---|---|---|
| Price | $1.82 | $7.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $4.70 | ★ $26.13 |
| AVG Volume (30 Days) | 12.1K | ★ 862.2K |
| Earning Date | 05-04-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $805,722,000.00 | $2,000,000.00 |
| Revenue This Year | $7.47 | N/A |
| Revenue Next Year | $8.12 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 19.66 | N/A |
| 52 Week Low | $1.65 | $4.50 |
| 52 Week High | $3.38 | $10.06 |
| Indicator | STKS | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 45.24 | 47.15 |
| Support Level | $1.69 | $6.95 |
| Resistance Level | $2.03 | $7.39 |
| Average True Range (ATR) | 0.09 | 0.44 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 22.65 | 18.55 |
The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through three segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.